CBLB612 is a synthetic lipopeptide. It is a toll-like receptor 2 (TLR2) agonist that acts as a powerful inducer and mobilizer of hematopoietic stem cells (HSCs).
Preclinical studies in mice and non-human primates (NHPs) have shown CBLB612 to activate HSCs to a greater degree than marketed biologic agents. These studies have also demonstrated a potent synergistic effect in mice and NHPs when combined with current standards of care.
Cleveland Biolabs is currently considering applications for CBLB612 in patient populations with high unmet medical needs that could most benefit from this novel biologic. Stem cell mobilization is important in many patient populations with cancer.
A Phase 1 study of CBLB612 is currently ongoing in the Russian Federation to assess the safety and tolerability of administrations of CBLB612 in healthy subjects and to characterize the type, quantity and timing of HSC mobilization in these subjects.